Common Clover Plant May Harbor Anti-CML Compounds
Posted: Tuesday, March 10, 2020
Polyphenols in a species of clover found in Europe and Asia, commonly used as a fodder crop for cattle, may prove to form the basis of treatments for chronic myeloid leukemia (CML). Senior author Lucia Altucci, MD, PhD, of the University of Campania Luigi Vanvitelli, Naples, Italy, and colleagues published their preclinical research on Trifolium repens, or white clover, in the journal Cells. The plant’s isoflavonoid-rich fraction, they described, “showed high cytotoxic effects in CML K562 cells, with IC50 values of 1.67 and 0.092 mg/mL, respectively.”
Specifically, the block of cell growth was linked to complete inhibition of BCR-ABL/STAT5 and to activation of the p38 signaling pathways. Normal cells, however, were not affected.
In various parts of the world, T repens is used to absorb heavy metals from soil, whereas in some regions of Turkey, it is known as an effective expectorant, antiseptic, and analgesic. Results of research published in 2019 demonstrated that the aqueous phenolic fraction extracted from T repens has a hepatoprotective function.
Dr. Altucci and her team used an MTT assay and Western blotting to analyze the effects of T repens’ total extract and of each fraction on cancer cell proliferation. “Our findings suggest that the development of novel compounds derived from phytochemical molecules contained in Trifolium [repens] might lead to the identification of new therapeutic agents active against CML,” they concluded.
Disclosure: The study authors reported no conflicts of interest.